MiNK Therapeutics, Inc. INKT
At closeNov 6, 2026, 4:00 PM EST
After hours · Nov 6, 4:00 PM ET
- YTD
- -7.17%
- 1 year
- -24.23%
- Market cap
- 52.82M
- EPS (ttm)
- -2.39
- Shares out
- 39.55M
- Forward P/E
- -1.17
- YTD return
- -7.17%
- 1-year return
- -24.23%
- Volume
- 7.67K
- Avg volume
- 14.13K
- Open
- 9.82
- Previous close
- 9.94
- Day's range
- 9.82 – 10.88
- 52-week range
- 8.56 – 14.21
- Beta
- 0.05
- Analysts
- Strong Buy
- Price target
- 6.50 (-37.2%)
- Earnings date
- Aug 13, 2024
ALL -109.65 (-91.38%)
Key statistics
- Enterprise value
- 22.96M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -8.16M
- Total cash
- 9.31M
- Total debt
- 4.41M
- Return on equity
- 0.00%
- Short % of float
- 0.35%
- 50-day average
- 0.68846
- 200-day average
- 0.846145
Analyst view
Consensus: strong buy
- Target (low)
- 4.00
- Target (mean)
- 6.50
- Target (high)
- 9.00
- Strong buy1
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 13, 2024
Expected Aug 13, 2024. Consensus EPS estimate -0.05.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.08 | -0.05 | +0.03 | +37.50% |
| Aug 13, 2024 | Jun 1, 2024 | -0.10 | — | — | — |
| Aug 13, 2024 | Jun 1, 2024 | -0.10 | -0.07 | +0.03 | +30.00% |
| May 14, 2024 | Mar 1, 2024 | -0.16 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | -0.16 | -0.11 | +0.05 | +31.25% |
| Mar 21, 2024 | Dec 1, 2023 | -0.15 | -0.16 | -0.01 | -6.67% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 15, 2024 | Baird | main | Outperform | Outperform |
| Nov 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 9, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 13, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 21, 2024 | HC Wainwright & Co. | main | Buy | Buy |
About MiNK Therapeutics, Inc.
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company has a collaboration with autonomous therapeutics, inc. to develop novel therapies targeting metastatic tumors. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- minktherapeutics.com
News
MiNK Therapeutics Presents Preclinical Cancer Data For iNKT Cell Therapy Platform At SITC 2026 
HC Wainwright & Co. Assumes MiNK Therapeutics at Buy, Announces Price Target of $38 
MiNK Therapeutics To Hold Webcast On Nov. 11 To Review Financial Results, Offer Update On Its Clinical Development Of AgenT-797 
MiNK Therapeutics to Report Third Quarter 2026 Results and Outline Progress in Randomized Clinical Development and Scalable iNKT Cell Therapy 
B. Riley Securities Reiterates Buy on MiNK Therapeutics, Raises Price Target to $50 
MiNK Therapeutics Q2 2026 Earnings Call: Complete Transcript - MiNK Therapeutics Q2 EPS $(0.62) Misses $(0.60) Estimate
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session 
Earnings Scheduled For May 15, 2026
Your note
Sign in to keep a note on INKT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AGENUS, INC. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Oct 15, 2023 | 21,772,900 |
| ARMEN GARO H. | Director | Sale | May 4, 2023 | 1,866,400 |
| BALDONI JOHN | Director | Stock Award(Grant) | Aug 31, 2023 | 41,193 |
| BEHNER PETER | Director | Stock Award(Grant) | Nov 28, 2024 | 133,634 |
| BUELL JENNIFER | Chief Executive Officer | Conversion of Exercise of derivative security | Sep 26, 2023 | 1,076,460 |
| CORVESE BRIAN J | Director | Stock Award(Grant) | Nov 28, 2024 | 426,283 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 0.59% | 234,182 | 115.03K | Sep 29, 2024 |
| Longbow Finance Sa | 0.42% | 166,666 | 81.87K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.27% | 106,687 | 52.40K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.25% | 97,981 | 48.13K | Sep 29, 2024 |
| Blackrock Inc. | 0.22% | 88,126 | 43.29K | Sep 29, 2024 |
| HighTower Advisors, LLC | 0.13% | 51,728 | 25.41K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.37% | 148,229 | 72.81K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.22% | 85,953 | 42.22K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.14% | 56,823 | 27.91K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.06% | 22,493 | 11.05K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.05% | 19,029 | 9.35K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.03% | 11,662 | 5.73K | Oct 30, 2024 |